Asterion Ai Inc.

Asterion Ai Inc., a Dallas, Texas-based for-profit corporation, develops and commercializes machine learning-powered electroencephalogram (EEG) systems for pre-hospital stroke diagnosis and triage. The company operates as a federal grant recipient, not a federal contractor, and has secured three prime grants totaling $1.8 million obligated across two federal agencies since 2022.

Asterion's federal footprint centers on the National Science Foundation and the National Institute for Minority Health and Health Disparities (part of the National Institutes of Health, Department of Health and Human Services). The NSF accounts for two awards under the Small Business Innovation Research (SBIR) program: a Phase I project grant awarded September 15, 2022 (completed August 31, 2024) and a $1.25 million Phase II Cooperative Agreement under the Technology, Innovation, and Partnerships program (CFDA 47.084), effective August 1, 2025 through July 31, 2027. The NIMHD awarded a $314,363 project grant on August 5, 2026 under the Minority Health and Health Disparities Research program (CFDA 93.307), with performance through July 31, 2027.

Work performed in Dallas addresses a specific clinical gap: enabling rapid, objective differentiation of ischemic versus hemorrhagic stroke and detection of large vessel occlusion (LVO) in the pre-hospital setting using machine learning classification of EEG signals. The NSF Phase II project expands multi-center clinical validation, refines user experience for emergency personnel, and commercializes the underlying algorithm, targeting an estimated $2 billion market opportunity by reducing time to intervention and optimizing patient routing to endovascular-capable centers. The NIMHD grant specifically targets rural stroke disparities, where patients are 50 percent less likely to receive intravenous thrombolysis and experience 8 percent higher mortality than urban patients. Both active grants have ultimate completion dates through July 31, 2027, placing both awards inside the next twenty-four-month recompete window.